Loading...
Bilateral Trade Intelligence · $32.1M Total Trade · 41 Foreign Suppliers · 33 Indian Buyers · DGFT Verified · Updated March 2026
India imported $32.1M worth of pharmaceutical formulations from Sweden across 302 verified shipments, from 41 foreign suppliers to 33 Indian buyers. The top suppliers are M/S. ASTRAZENECA AB ($16.5M) and ASTRAZENECA AB ($5.6M). The leading products are Metoprolol ($26.0M) and Osimertinib ($2.6M). Average shipment value: $106.5K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Metoprolol | $26.0M | 80.9% |
| 2 | Osimertinib | $2.6M | 8.2% |
| 3 | Dapagliflozin | $942.7K | 2.9% |
| 4 | Budesonide | $898.1K | 2.8% |
| 5 | Saxagliptin | $845.6K | 2.6% |
| 6 | Amino | $211.1K | 0.7% |
| 7 | Sodium | $172.9K | 0.5% |
| 8 | Nivolumab | $155.6K | 0.5% |
| 9 | Protein | $88.7K | 0.3% |
| 10 | Metformin | $87.6K | 0.3% |
| 11 | Plasma | $45.4K | 0.1% |
| 12 | Cabozantinib | $24.6K | 0.1% |
| 13 | Olaparib | $12.0K | 0.0% |
| 14 | Omeprazole | $9.6K | 0.0% |
| 15 | Esomeprazole | $8.7K | 0.0% |
India imports 20+ pharmaceutical formulations from Sweden with a combined trade value of $32.1M. Key products include Metoprolol ($26.0M), Osimertinib ($2.6M), Dapagliflozin ($943K), Budesonide ($898K), Saxagliptin ($846K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 302 verified Indian Customs (DGFT) shipment records.
India exported pharmaceuticals worth $32.1M to Sweden across 302 verified shipments.
1. M/S. ASTRAZENECA AB — $16.5M. 2. ASTRAZENECA AB — $5.6M. 3. M S ASTRAZENECA AB — $3.5M. Total: 41 suppliers.
1. ASTRAZENECA PHARMA INDIA LIMITED — $28.9M. 2. FRESENIUS KABI INDIA PRIVATE LIMITED — $238.7K. 3. JOHNSON & JOHNSON PRIVATE LIMITED — $226.4K. 33 buyers total.
1. Metoprolol ($26.0M, 80.9%); 2. Osimertinib ($2.6M, 8.2%); 3. Dapagliflozin ($942.7K, 2.9%); 4. Budesonide ($898.1K, 2.8%); 5. Saxagliptin ($845.6K, 2.6%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $32.1M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
These are the top pharmaceutical products exported from India to Sweden, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Sweden buyers, regulatory requirements, and logistics for that specific product corridor. Products include Metoprolol ($26.0M), Osimertinib ($2.6M), Dapagliflozin ($943K), Budesonide ($898K), Saxagliptin ($846K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
41 Indian pharmaceutical companies export finished formulations to Sweden. Leading exporters include M/s. Astrazeneca Ab, Astrazeneca Ab, M S Astrazeneca Ab, Ms Astrazeneca Ab. The top exporter accounts for 51.3% of total India–Sweden pharma exports. Source: Indian Customs (DGFT).
33 companies in Sweden import pharmaceutical formulations from India. Top buyers include Astrazeneca Pharma India Limited, Fresenius Kabi India Private Limited, Johnson & Johnson Private Limited, Dhl Logistics Private Limited. The largest buyer accounts for 89.8% of India–Sweden pharma imports. Source: Indian Customs (DGFT).
$106.5K per consignment across 302 shipments.
41 Indian companies. Largest: M/S. ASTRAZENECA AB with $16.5M.
TransData Nexus covers 41 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 302 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
41 Exporters
33 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists